Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26025461 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26025460 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029347 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029319 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029348 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029346 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029322 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029344 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL26029321 | 0.95 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A | |
| SCHEMBL23790864 | 0.93 | CYP3A4 (0.64) | CYP3A4CYP2C9ADORA3DNPH1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | Atea Pharmaceuticals, Inc. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364121-A1 | NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY | NSUN2, ACE2, PNP | CYP3A4 344/4885CYP2C9 1644/4885ADORA3 2864/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CYP3A4 1696/4885CYP2C9 944/4885ADORA3 105/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CYP3A4 1696/4885CYP2C9 944/4885ADORA3 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.